AbbVie · 2 days ago
Senior Finance Analyst, R&D Business Development & Alliances
AbbVie is a company dedicated to discovering and delivering innovative medicines and solutions. They are seeking a Senior Finance Analyst to assist with financial planning and analysis for R&D Collaboration Alliances, including building R&D cost forecasts and providing finance support for newly executed deals.
BiotechnologyFinancial ServicesHealth CareMedicalPharmaceuticalVenture Capital
Responsibilities
Prepare R&D costing models for BD assessments, working with cross functional contacts to collect model inputs and assumptions
Provide Finance support for the transition and operationalization of newly executed deals
R&D BD Summary maintenance and distribution to leadership
Leads ad hoc analysis, projects and process improvements as needed
Qualification
Required
Bachelors degree in Accounting or Finance
Minimum 2-3 years+ of progressive and related experience
Strong financial, analytical, and problem-solving skills
Attention to detail, proactive thinker and quick decision-making skills
Able to work well independently and in a team-oriented environment
Excellent communication skills with varying levels of the organization
Proficient Excel skills required
Preferred
Knowledge of SAP and BPC a plus
Benefits
Paid time off (vacation, holidays, sick)
Medical/dental/vision insurance
401(k)
Company
AbbVie
AbbVie is a biopharmaceutical company focused on immunology, oncology, neuroscience, virology, and aesthetics. It is a sub-organization of AbbVie.
H1B Sponsorship
AbbVie has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (273)
2024 (190)
2023 (225)
2022 (284)
2021 (186)
2020 (186)
Funding
Current Stage
Public CompanyTotal Funding
$15B2024-02-27Post Ipo Debt· $15B
2023-03-08Post Ipo Equity· $0.25M
2012-12-20IPO
Leadership Team
Recent News
2026-01-20
2026-01-20
2026-01-20
Company data provided by crunchbase